A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

To join this study, participants generally need to be at least 12 years old. If you're between 12 and 18, you also need to weigh at least 40 kg. You must have been diagnosed with advanced melanoma, either Stage III that can't be removed, or Stage IV which means it has spread. Your general health and ability to do daily activities should be quite good, as assessed by a doctor.

There are some reasons why you might not be able to join. For example, if you have a specific type of eye melanoma, or if you've had a heart condition called myocarditis. Also, if you're taking high doses of certain medications that affect your immune system, you might not be eligible. The study team will check all these details carefully with you.

If you join this study, you will receive the usual combination therapy (nivolumab + relatlimab) either as an injection under the skin or through a drip into a vein. The study team will explain which method you'll receive. You will have regular visits to the clinic for your treatments and check-ups. These visits will involve blood tests, physical examinations, and scans (like CT or MRI scans) to see how you're responding to the treatment and to monitor your health.

The exact number and timing of visits will depend on how your treatment progresses, but you should expect regular appointments. There will also be follow-up appointments after your treatment ends to continue monitoring your health. The total duration of your participation in the study, including follow-up, will be determined by the study plan and your individual response. All procedures will be explained in detail by the study team.